Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday announced the publication of Phase 2 SARA-INT trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle.
The findings confirm the company's readiness to advance to Phase 3 in the development of a potential treatment for sarcopenia.
BIO101 demonstrated a clinically meaningful improvement in the 400-metre walk test, the study's primary endpoint, and showed a strong safety profile with no serious adverse events. The treatment was particularly effective in high-risk populations, including slow walkers and patients with sarcopenic obesity.
With no approved therapeutic solutions for sarcopenia, which affects up to 194 million people globally, Biophytis remains at the forefront of innovation in this field. The company is making regulatory progress for Phase 3 trials and is in active discussions with a major pharmaceutical partner in China and other industrial collaborators in Asia.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025